ReviewNPJ precision oncology2019
Liquid biopsy: one cell at a time.
Review in NPJ precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Super homotypic targeting by surface engineering of extracellular vesicles.Nature biomedical engineering · 2026Article
- Article
- Mitochondrial metabolism in cancer stem cells (CSCs): molecular and diagnostic implications.Frontiers in molecular biosciences · 2026Review
- Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- The role of advanced diagnostics on precision medicine in hemato oncology.Discover oncology · 2025Review
- Circulating tumor cells and clusters as liquid biomarkers for the diagnosis and prognosis of neuroblastoma.BMC cancer · 2025Article
- Detection of circulating tumor cells in patients with lung cancer using a rare cell sorter: a pilot study.BMC cancer · 2024Article
- Diagnostic Performance of Epithelial Cell Adhesion Molecule for Early Detection of Hepatocellular Carcinoma Among HCV High-Risk Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.Cancers · 2024Review
- Liquid Biopsy Instrument for Ultra-Fast and Label-Free Detection of Circulating Tumor Cells.Research (Washington, D.C.) · 2024Article
- Analytical Validation of a Spiral Microfluidic Chip with Hydrofoil-Shaped Pillars for the Enrichment of Circulating Tumor Cells.Biosensors · 2023Article
- Review
- Microfluidics engineering towards personalized oncology-a review.In vitro models · 2023Review
- Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis.International journal of molecular sciences · 2023Review
- Circulating Tumor Cells in Breast Cancer: A Step Toward Precision Medicine for Real-Time Monitoring of Metastasis.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer.Cancers · 2023Review
- Computational single cell oncology: state of the art.Frontiers in genetics · 2023Review
- Advances in early detection methods for solid tumors.Frontiers in genetics · 2023Review
- CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity.Heliyon · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an alternative target to surgically resected tissue specimens, liquid biopsy has gained much attention over the past decade. Of the various circulating biomarkers, circulating tumor cells (CTCs) have particularly opened new windows into the metastatic cascade, with their functional, biochemical, and biophysical properties. Given the extreme rarity of intact CTCs and the associated technical challenges, however, analyses have been limited to bulk-cell strategies, missing out on clinically significant sources of information from cellular heterogeneity. With recent technological developments, it is now possible to probe genetic material of CTCs at the single-cell resolution to study spatial and temporal dynamics in circulation. Here, we discuss recent transcriptomic profiling efforts that enabled single-cell characterization of patient-derived CTCs spanning diverse cancer types. We further highlight how expression data of these
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.